5Acar J, lung B, Boissel JP, et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation, 1996,94:2107-2112.
6Uetsuka Y, Hosoda S, Kasanuki H, et al. Optimal therapeutic range for oral anticoagulants in Japanese patients with prosthetic heart valves: a preliminary report from a single institution using conversion from thrombotest to FT-INR. Heart Vessels, 2000,15:124-128.
7Mori T, Asano M, Ohtake H, et al. Anticoagulant therapy after prosthetic valve replacement -optimal PT-INR in Japanese patients.Ann Thorac Cardiovasc Surg, 2002,8:83-87.
8Chenhsu RY, Chiang SC, Chou MH, et al. Long-term treatment with warfarin in Chinese population. Ann Pharmacother, 2000,34:1395-1401.
9Hirsh J, Dalen JE, Deykin D, et al. Oral antlcoagulants:mechanism of action. Clinical effectiveness and optimal therapeutic range. Chest, 1992,102(Suppl) :S312-S326.
10Stein PD, Alpert JS, Copeland J, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.Chest, 1992,102(Suppl) :S445-S455.
